Naia Pharmaceuticals Status
The company raised an undisclosed amount of funding from Cedars-Sinai on April 3, 2017.
Operator of a biopharmaceutical company created to develop drugs for Short Bowel Syndrome. The company develops clinically advance drug candidates for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases enabling health care providers to treat gastrointestinal problems and disorders and reduce recovery times.
Year Founded
2014
General Information
-
Website
-
Business Status
Startup
-
Ownership Status
Privately Held (backing)
-
Financing Status
Angel-Backed
Naia Pharmaceuticals News and Updates
New York Knicks Legend Willis Reed Dies at 80
AOL | March 22, 2023
Progestagen-only contraceptives carry similar, small breast canc
News Channel Nebraska | March 21, 2023
Newsom announces $50 million contract to make California's own ...
Oil City Derrick | March 18, 2023
FDA advisers vote in support of Paxlovid approval for Covid-19 ...
News Channel Nebraska | March 16, 2023
Kamaru Usman Net Worth 2023, Salary and Earnings
EssentiallySports | March 14, 2023
Judge delays execution of Idaho inmate Gerald Pizzuto, halts latest death warrant
AOL | March 10, 2023
Naia Pharmaceuticals Primary Industry Sector / Group / Code
Naia Pharmaceuticals's Trends
Headquarters
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ CountryUnited States
Naia Pharmaceuticals's Keywords
mood_badFeed is empty.
Add a review